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Summary 
The human immunodeficiency virus (HIV) Rev protein is essential for viral structural protein 
expression (Gag, Pol, and Env) and, hence, for viral replication. In transient transfection assays, 
mutant forms of Rev have been identified that inhibit wild-type Rev activity and therefore suppress 
viral replication. To determine whether such transdominant Rev proteins could provide long- 
term protection against HIV infection without affecting T  cell function, T leukemia cell lines 
were stably transduced with a retroviral vector encoding a transdominant mutant of the Rev 
protein, M10.  While all the M10-expressing cell lines remained infectable by HIV-1,  these same 
cells failed to support a productive replication cycle when infected with a cloned isolate of HIV-1. 
In addition, two out of three M10-expressing CEM clones were also resistant to highly productive 
infection by a heterogeneous HIV-1  pool. Expression of M10 did not affect induction of HIV 
transcription mediated by the KB regulatory element or Tat. Importantly, constitutive expression 
of Rev M10 did not alter the secretion of interleukin 2 in response to mitogen stimulation of 
Eb4 and Jurkat ceils. The inhibition of HIV infection in cells stably expressing a transdominant 
Rev protein, in the absence of any deleterious effect on T  cell function, suggests that such a 
strategy could provide a therapeutic effect in the T lymphocytes of acquired immunodeficiency 
syndrome patients. 
e][~ ?lication of human retroviruses, unlike that of their avian 
and murine counterparts, is dependent upon virally en- 
coded transactivator proteins.  These proteins  function by 
specifically modulating host cell processes and must, there- 
fore, interact with host cell factors.  One approach to the in- 
hibition of retroviral infection is to express transdominant 
forms of viral transactivators that interfere with their func- 
tion (1, 2).  However, should inhibition be achieved by the 
interaction of the mutant protein with a factor essential for 
normal cell function, then such a strategy becomes contrain- 
dicated. 
The HIVol Rev protein is encoded by a fully spliced viral 
mRNA synthesized early in virus infection (3). Rev activates 
the cytoplasmic expression of unspliced viral mRNAs (4-7), 
presumably interacts with host cell factors (8-11), and may 
be important for regulating virus latency (11, 12). Towards 
the COOH terminus of Key, there is a well-conserved leucine- 
rich domain that is absolutely essential for function (13-16). 
Mutations in this region give rise to defective proteins that 
are transdominant inhibitors of Key function in transient trans- 
fection assays (13-16).  In vitro analyses have suggested that 
inhibition occurs by the formation of nonfunctional hetero- 
meric Rev multimers unable to interact with the host cell 
factors required for the cytoplasmic expression of unspliced 
viral mRNAs (17). Together, these observations suggest that 
the expression of transdominant negative mutants of Rev may 
represent a potential strategy for anti-HIV therapy. In this 
report, the effects of stable expression of a Rev transdominant, 
M10,  in leukemic T  cell lines are examined. 
Materials and Methods 
Preparation of Retroviral Vectors and Cell Transduction.  The PLJ 
plasmid (18) was digested with BamHI, filled in with Klenow, and 
digested with Sail. This fragment was ligated to a 592-bp insert 
derived from GST/M10 (17), prepared by digestion with NcoI, in- 
cubation with Klenow enzyme, followed by digestion with XhoI. 
The PLJ cRev M10 plasmid was introduced by calcium phosphate 
transfection into the ecotropic r  virus-packaging cell line (19). 
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the amphotropic r  line, which was then selected 
in G418 (1.0 mg/ml). 24 clones were analyzed by titration for G418 
resistance,  and three producer clones were selected with titers of 
"~10S/ml. Viral supernatants were incubated with CEM, Jurkat, 
and Eb4 cells (5  x  10S/ml) for 4-8 h each day on four consecu- 
tive days, with cells maintained otherwise in RPMI 1640 with 10% 
FCS.  Cells were selected in G418 (1.0 mg/ml) and subclones  of 
G418-resistant  CEM cells were isolated by limiting dilution. Sub- 
clones were tested for PLJ-cREV M10 provirus by Southern blot 
analysis by digesting high molecular weight DNA with XbaI and 
probing for a 4.49-kb fragment with the 592-bp cREV M10 in- 
sert. As a control, CEM cells were transduced with a ~-galactosidase 
retroviral vector that confers G418 resistance,  BAG, as previously 
described (20,  21). 
Construction ofpIIIB/CAT.  The replication-competent, chlor- 
amphenicol  acetyltransferase  (CAT)-expressing  proviral  clone, 
plIIB/CAT, is similar in design to vectors described previously by 
Terwilliger et al. (22). In plIIB/CAT, the CAT gene has replaced 
the 5' portion of the viral nefgene and is therefore, like Nef, ex- 
pressed independent of Rev. To construct this vector, an NcoI site 
was introduced at the initiation codon of nefin the plIIB proviral 
clone (23) by targeted mutagenesis (AGATGG-~ACCATGG). A 
681-bp NcoI-Asp718 CAT gene fragment was generated by digesting 
the products of a PCIL that had been performed with primers de- 
signed to introduce these sites at the 5' and 3' ends of CAT. This 
fragment was inserted between the introduced NcoI site and the 
Asp718 site (HXB-3 isolate, sequence coordinates 8374 and 8593, 
respectively) 70 bp upstream of the 5' boundary of the 3' LTR U3 
region. To partially compensate for the increased length of the virus 
genome, the sequences of the 3' LTR U3 region between the EcoRV 
sites (sequence coordinates 8698 and 8998) were deleted. The net 
increase in genome length is therefore only 163 nucleotides. 
Cell Culture and HIV Infection.  CEM subclones were infected 
with 0.5 ml of ftltered virus supernatant derived from highly produc- 
tive infections of CEM cells with the plIIB or plIIB/CAT molec- 
ular clones  (23), or H9 cells with the uncloned, heterogeneous 
HTLV-IIIB isolate (24).  Cells were maintained at 0.5-2.5  x  106 
cells/ml in RPMI 1640 containing 10% FCS. Virus replication was 
monitored over a 4-wk period using an ELISA system for soluble 
p24S's expression (DuPont, NEN, Inc., Billerica,  MA). CAT ac- 
tivity was measured 48 h after infection after repeated (four) cell 
washes. As a negative control, virus was heat inactivated by incu- 
bation at 56~  for 60 min. 
11:2 Secretion.  Ib2 gene expression was stimulated by the addi- 
tion of PMA (40 nM) in EL4 cells or PMA (40 nM), and PHA 
1/~g/ml) in Jurkat cells. Supernatant was collected 24 h after stim- 
ulation. Secreted IL-2 in culture supernatants was measured with 
the IL-2-dependent  CTLL cell line and a colorimetric assay (see 
Fig.  4). Cell proliferation expressed as ODsT0 is on the ordinate. 
The concentration of supernatant in uninduced (-) or stimulated 
(+) EL4 or Jurkat cells was 10%. Values represent the average of 
triplicate determinations, and SDs were <10%. 
Results 
An  amphotropic retroviral vector that  encodes the M10 
mutant of Rev, as well as a control vector expressing ~-galac- 
tosidase, were used to stably transduce the leukemic T  cell 
lines CEM,  EL4, and Jurkat.  To analyze the effects of con- 
stitutive Rev M10 expression in long-term cell culture, sub- 
clones derived from the CEM-transduced  cells were estab- 
lished.  Immunoprecipitation  analysis  with  an  anti-Rev 
antiserum confirmed that subclones 3, 4, and 5, but not the 
control cells, expressed the transdominant Rev protein (data 
not shown). Continued expression of the cell surface receptor 
CD4 was confirmed by FACS  |  analysis  (data  not shown). 
These cell lines were next tested for their ability to support 
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Figure 1.  The inhibitory effect of Rev M10 protein on the replication of cloned (A) and uncloned (B) HIV-1 in CEM cells. The PLJ-M10 and 
PLJ-BAG retroviral vectors (20) were used to stably transduce CEM cells (Materials and Methods). After subcloning, 5  x  10  s cells expressing BAG 
(11) or Rev M10 (1"3) subclone  3; (A) subclone  4; (O) subclone 5 were infected. Results are representative  of two (A) or four (B) independent experiments. 
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Figure  2.  Susceptibility of CEM cells to initial infection by HIV-1. The 
indicated CEM subclones (5  x  10  s cells) were either mock infected with 
media alone, infected with heat-inactivated  (HI) virus, or infected with 
virus derived from plIIB/CAT. Cells were maintained as described in the 
legend to Fig.  1, washed at 48 h, and assayed for CAT activity.  Results 
are representative  of two independent  experiments. 
a productive infection of HIV-1. All three Rev M10-expressing 
subclones were highly resistant to productive infection with 
virus generated from a molecular clone (Fig.  1 A) (23). In 
contrast, cells transduced with the B-galactosidase vector were 
similar in susceptibility to nontransduced CEM cells (Fig. 
1 A, and data not shown). When infected with the hetero- 
geneous HTLV-IIIB pool (24),  two of the M10-expressing 
CEM subclones displayed resistance to highly productive in- 
fection (subclones 3 and 5, Fig. 1 B). The continuous produc- 
tion of low, but detectable levels of virus by these cultures 
suggested that these subdones were infected by HIV, but that 
virus failed to replicate efficiently in these cells. In contrast, 
subclone 4 displayed only a slight delay in the pattern of viral 
spread relative to control cells. We have recently reconfirmed 
the validity of transdominant Rev-mediated protection of cells 
against HIV infection using an alternative transdominent mu- 
tant of Rev, M32 (11), CEM-SS cells (25), and a double-copy 
retroviral  vector,  N2A (26) (data  not shown). 
If the observed resistance of the CEM cells to productive 
HIV-1 infection was a direct consequence of R.ev M10 ex- 
pression,  then the cells should still be susceptible  to initial 
infection. To address this issue, a proviral expression vector 
plIIB/CAT was constructed in which the viral nefgene was 
replaced with the bacterial CAT gene. Because the Nef pro- 
tein is expressed early after HIV-1 infection and is therefore 
independent of Rev (3), it is predicted that, in cells infected 
with plIIB/CAT virus, the induction of CAT activity shortly 
after exposure to virus would be a measure of early viral gene 
expression and, hence, the number of infectious events. As 
anticipated, all the CEM lines expressed readily detectable 
CAT activity 48 h after infection with the plIIB/CAT virus 
(Fig. 2). No increase in CAT activity was detected in cells 
infected with heat-inactivated (HI) virus relative to mock- 
infected cells, thus demonstrating that detection of CAT was 
a consequence of retroviral infection and not residual inoculum. 
To evaluate the effect of Rev M10 on T cell function, the 
CEM subclones  were transfected  with HIV-CAT reporter 
plasmids. Mitogen and cytokine induction of the HIV LTR 
is dependent on an 11-bp sequence recognized by the NF-KB 
transcription factor (27).  To determine whether the sensi- 
tivity of the HIV LTR to NF-KB was affected by the M10 
mutant, CAT activity in each CEM subclone was determined 
after PMA induction. Activation mediated by the KB site was 
indistinguishable between the three subclones of CEM M10, 
compared with the B-galactosidase control (Fig. 3 A). In ad- 
dition, stimulation by the HIV-1 Tat protein, through the 
TAR region of the HIV-CAT reporter, was also unaffected 
in subclones that stably express M10 protein (Fig. 3 B). To 
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Figure 3.  Stimulation  of HIV-1 transcription  by NF-KB (A) or Tat (B) in CEM cells that stably express the Rev M10 protein.  To analyze NF-KB 
inducibility  (.4),  the indicated  CEM subclones were transfected  with 10 #g of HIV-CAT plasmid or a mutant  KB HIV-CAT plasmid before PMA 
stimulation.  To analyze Tat function (B), these subclones were cotransfected  with HIV-CAT  or with a derivative bearing  a defective TAR element 
(29).  Cells were untreated  (-) or incubated  (+) with PMA (20 ng/ml), and CAT assays were performed  as previously  described (27). 
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Figure 4.  Induction  of II.,2 secretion after stimulation  in (A) EL-4  cells 
and (B) Jurkat cells that express the Rev MIO protein. 
examine more thoroughly the effect of constitutive M10 ex- 
pression on the immune function of cells, transduced Jurkat 
and EL-4 cell lines were evaluated for their ability to secrete 
IL-2 after mitogen activation.  No difference was observed with 
respect to IL.2 secretion in either cell compared to controls 
(Fig. 4), thus demonstrating that induction of this lymphokine 
in cells that stably expressed the Rev transdominant protein 
is unaffected. 
Discussion 
The introduction into susceptible cells of mutant forms 
of HIV-1 proteins that then interfere with viral replication 
represents an attractive approach to the treatment of HIV-1 
infection (1, 2).  Although analogues of HIV-1 nucleic acid 
structures, such as TAR or RRE, have been used to inhibit 
HIV replication in cells (28),  the potential of mutant viral 
proteins to achieve this effect, and their ability to interfere 
with normal cellular function, remain unknown. Here we 
demonstrate a substantial inhibition of HIV-1 replication in 
the majority of T  cells that constitutively express the Rev 
M10 transdominant mutant. In addition, we show that the 
transdominant Rev-expressing lines vary in their initial sus- 
ceptibility to HIV-1 infection by no more than twofold rela- 
tive to the control, BAG-expressing,  ceils (Fig. 2). These data 
support the conclusion, therefore, that resistance of the CEM 
cells to HIV-1 infection is directly due to the M10 protein, 
which inhibits productive infection by preventing expression 
of viral structural proteins. The mechanism of Roy M10 pro- 
tection has been analyzed previously (17). The RNA binding 
and multimerization domains of M10 are intact, suggesting 
that the Rev M10 multimerizes and precludes the binding 
of wild-type Roy to the RRE and subsequent interactions 
with the cellular factors that facilitate the cytoplasmic ex- 
pression ofunspliced viral RNA (17). We speculate that sub- 
clone 4 displayed only a delay in the onset of acute infection 
with HTLV-IIIB (Fig.  1 B), because it appears  to show in- 
creased susceptibility to initial infection, as determined by 
the CAT infection experiment (Fig. 2), relative to the other 
lines. 
Importantly, expression of Rev M10 protein did not inter- 
fere with the induction of several T cell activation genes, in- 
cluding the NF-KB transcription factor, those required for 
Tat function, and the multiple regulatory proteins that con- 
trol Ib2 synthesis. Although the possibility remains that Rev 
M10 may affect other activation pathways, these results sug- 
gest that stable  expression of Rev M10 does not adversely 
affect T cell function globally. The Rev M10 protein there- 
fore represents a gone product that might preclude efficient 
HIV-1 replication without adversely affecting T  cell func- 
tion. Although differential protection by Roy M10 was ob- 
served in separate subclones with the uncloned virus pool, 
resistance need not be conferred equally on all T cells to pro- 
vide a therapeutic effect. For example, T cell clones rendered 
resistant to HIV-1  could proliferate to reconstitute the im- 
mune system of an infected host. Because multiple cells can 
be transduced, protection against HIV-l-induced disease might 
be achieved by transducing sufficiently large numbers of cells 
with Rev M10. This gone could be readily introduced into 
peripheral CD4 + T  cells or eventually into progenitor cells 
that give rise to mature CD4 + populations.  This strategy 
might, therefore, be used to slow the progression of AIDS 
in asymptomatic HIV-l-infected patients or, possibly, might 
be used to restore immune function in individuals that have 
progressed to later disease  stages. 
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